Forward Looking Statement The forward-looking statements, objectives and targets contained herein are based on the Company's management strategy, current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. Furthermore, the Research and Development process involves several stages each of which involve the substantial risk that the Company may fail to achieve its objectives and be forced to abandon its efforts with regards to a product in which it has invested significant sums. Therefore, the Company cannot be certain that favorable results obtained during pre-clinical trials will be confirmed subsequently during clinical trials, or that the results of clinical trials will be sufficient to demonstrate the safe and effective nature of the product concerned. DBV technologies' business is subject to the risk factors outlined in its registration documents filed with the French Autorité des Marchés Financiers.
|David Schilansky Chief Financial Officer DBV Technologies Tél. : +33(0)1 55 42 78 75 email@example.com Alan S. Roemer U.S. Investor Relations The Trout Group Tél. : +1 646 378-2945 firstname.lastname@example.org New Cap. Financial Communication and investor relations Emmanuel Huynh / Valentine Brouchot Tél. : +33(0)1 44 71 94 94 email@example.com Ronald Trahan, APR Press relations Ronald Trahan Tél. : +1 508 359 4005 firstname.lastname@example.org|
# # # # #
Dr. Hugh Sampson presents Epicutaneous Immunotherapy for Food Allergy http://hugin.info/156437/R/1749730/589402.pdfHUG#1749730